• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

荷瘤动物体内抗癌药物的药代动力学研究。

Pharmacokinetic studies of anticancer drugs in tumor-bearing animals.

作者信息

Donelli M G, D'Incalci M, Garattini S

出版信息

Cancer Treat Rep. 1984 Feb;68(2):381-400.

PMID:6697328
Abstract

The pharmacokinetics of antitumor agents is a relatively recent area of research, as lack of proper specific methodology for monitoring drug levels has always hampered major efforts. Although the relationship among administered dose, tissue concentration, and therapeutic and/or toxic effects remains extremely complex, a series of experimental and clinical studies provides information on the pharmacokinetic behavior of most anticancer agents in different conditions. This review article describes examples selected from the work of this Institute on several points which may be relevant to the use of these compounds: (a) factors influencing pharmacokinetics, such as genetic constitution of the host, presence of the tumor, dose, route of administration and schedule, organ insufficiency, and interactions with other drugs; (b) drug distribution in host tissues in relation to toxic effects; (c) drug distribution to secondary tumors (metastases); (d) importance of active metabolites; and (e) drug distribution and binding to intracellular target sites. An analysis of these factors shows that many aspects are still very poorly understood and require considerable further study.

摘要

抗肿瘤药物的药代动力学是一个相对较新的研究领域,因为缺乏监测药物水平的适当特定方法一直阻碍着主要研究工作。尽管给药剂量、组织浓度以及治疗和/或毒性作用之间的关系仍然极其复杂,但一系列实验和临床研究提供了大多数抗癌药物在不同条件下药代动力学行为的信息。这篇综述文章从本研究所的工作中选取了一些例子,涉及与这些化合物使用可能相关的几个方面:(a) 影响药代动力学的因素,如宿主的遗传构成、肿瘤的存在、剂量、给药途径和方案、器官功能不全以及与其他药物的相互作用;(b) 与毒性作用相关的药物在宿主组织中的分布;(c) 药物向继发性肿瘤(转移瘤)的分布;(d) 活性代谢物的重要性;以及 (e) 药物向细胞内靶位点的分布和结合。对这些因素的分析表明,许多方面仍了解甚少,需要进行大量进一步研究。

相似文献

1
Pharmacokinetic studies of anticancer drugs in tumor-bearing animals.荷瘤动物体内抗癌药物的药代动力学研究。
Cancer Treat Rep. 1984 Feb;68(2):381-400.
2
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.顺式二氯(2-甲基吡啶)氨铂(II)(AMD473),一种新型空间位阻铂配合物:小鼠体内活性、毒理学及药代动力学
Clin Cancer Res. 1997 Nov;3(11):2063-74.
3
Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.对两种显示出对实体瘤有优先活性的新型噻吨酮(183577和232759)在小鼠体内进行的药代动力学研究。
Clin Cancer Res. 1997 Nov;3(11):2047-53.
4
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.通过将天然脂肪酸与紫杉醇共价偶联实现肿瘤靶向
Clin Cancer Res. 2001 Oct;7(10):3229-38.
5
Saturable metabolism and its relationship to toxicity.饱和代谢及其与毒性的关系。
Crit Rev Toxicol. 1981 May;9(2):105-50. doi: 10.3109/10408448109059563.
6
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.新型埃坡霉素B衍生物伊沙匹隆(BMS247550)针对儿童癌症模型的体内评估
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8. doi: 10.1158/1078-0432.CCR-05-0740.
7
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.一项关于口服二芳基磺酰脲类药物ILX-295501的I期药代动力学研究,该研究针对晚期实体恶性肿瘤患者,每4周为一个周期,每周给药一次,共给药3周。
Clin Cancer Res. 2003 Nov 15;9(15):5540-9.
8
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.抗癌药物在人体中的剂量依赖性代谢、治疗效果及毒性。
Drug Metab Rev. 1983;14(6):1145-63. doi: 10.3109/03602538308991425.
9
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.曲西他滨药代动力学和药效学的种属差异:对临床开发的影响。
Clin Cancer Res. 2004 Nov 15;10(22):7692-702. doi: 10.1158/1078-0432.CCR-04-0657.
10
Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.9-甲氧基-N,N-二甲基-5-硝基吡唑并[3,4,5-kl]吖啶-2(6H)-丙胺(PZA,PD 115934,NSC 366140)在小鼠体内的药代动力学:早期临床试验指南1
Clin Cancer Res. 1995 Aug;1(8):831-7.

引用本文的文献

1
Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone.编码小鼠醛氧化酶的cDNA的分子克隆:睾酮对其体内组织分布及调节作用
Biochem J. 1999 Jul 1;341 ( Pt 1)(Pt 1):71-80.
2
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.与血浆相比,5-氟尿嘧啶在人和鼠肿瘤中高浓度的持续保留。
Cancer Chemother Pharmacol. 1993;31(4):269-76. doi: 10.1007/BF00685670.
3
Predictive testing in cancer chemotherapy. II. In vitro.
Pharm Weekbl Sci. 1985 Aug 23;7(4):125-33. doi: 10.1007/BF02097248.
4
Predictive testing in cancer chemotherapy. I. In vivo.
Pharm Weekbl Sci. 1985 Jun 21;7(3):93-9. doi: 10.1007/BF01968709.
5
Anticancer drug pharmacodynamics.抗癌药药效学
Cancer Chemother Pharmacol. 1985;14(3):177-83. doi: 10.1007/BF00258112.
6
Perspectives in the treatment of cancer metastasis.癌症转移治疗的展望
Clin Exp Metastasis. 1987 Apr-Jun;5(2):105-24. doi: 10.1007/BF00058057.
7
Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
Cancer Chemother Pharmacol. 1987;20(3):239-42. doi: 10.1007/BF00570493.
8
The uptake of 3H-vincristine by a mouse carcinoma during a course of fractionated radiotherapy.在分次放射治疗过程中,小鼠癌对³H-长春新碱的摄取情况。
Br J Cancer. 1989 Sep;60(3):310-4. doi: 10.1038/bjc.1989.276.
9
The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice.
Cancer Chemother Pharmacol. 1990;27(2):106-10. doi: 10.1007/BF00689092.
10
The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.黄酮乙酸(NSC 347512)的组织水平与小鼠结肠肿瘤中位点依赖性抗肿瘤活性之间的关系。
Br J Cancer. 1991 Apr;63(4):541-5. doi: 10.1038/bjc.1991.127.